Skip to content
    PCVX
    Earnings call· Dec 2025(Q4 FY25)

    Vaxcyte Q4 FY25 earnings call PCVX

    Feb 24, 2026 Source

    Executive summary

    Vaxcyte Q4 FY25 — Advancing PCV Franchise with Key Clinical Milestones and Strengthened Financial Position

    Vaxcyte closed FY25 with significant progress in its pneumococcal conjugate vaccine franchise, initiating three pivotal Phase III studies for VAX-31 adult and completing enrollment for the VAX-31 infant Phase II study. The company also fortified its manufacturing and commercial readiness, supported by a robust balance sheet and recent equity offering, providing runway through 2028. This positions Vaxcyte for a catalyst-rich period with multiple clinical readouts expected over the next 12-18 months, including the resumption of its VAX-A1 program.

    Highlights

    5

    • Initiated OPUS Phase III program for VAX-31 adult PCV, with top-line data for OPUS-1 expected in Q4 2026.

    • Completed construction of dedicated large-scale manufacturing facility on time and on budget, supporting global commercial demand.

    • Strengthened financial position with $2.4 billion cash, cash equivalents, and investments as of December 31, 2025, and an additional $600.2 million net proceeds from a public equity offering.

    • Resumed development of VAX-A1 Group A Strep vaccine candidate, with a Phase I study expected to initiate this year.

    • VAX-31 is designed to cover 95% to 98% of circulating pneumococcal disease in the U.S. and Europe.

    Concerns

    2

    • Total expenses, particularly R&D, are expected to increase meaningfully in 2026 compared to 2025 due to manufacturing scale-up and increased clinical trials.

    • Capitalized costs are expected to trend down in 2026 as the dedicated manufacturing facility build-out is complete, shifting costs to expensed items.

    Guidance & targets

    7
    CategoryTargetConfidence
    VAX-31 Adult PCV (OPUS-1) Top-line Data
    Q4 2026
    high materiality
    High
    VAX-31 Adult PCV (OPUS-2 & OPUS-3) Readouts
    First half of 2027
    high materiality
    High
    VAX-31 Infant Phase II Study Data
    By the end of the first half of 2027
    high materiality
    High
    VAX-A1 Group A Strep Vaccine Phase I Study Initiation
    This year
    medium materiality
    High
    Cash Runway
    To at least the end of 2028
    high materiality
    High
    Total Expenses
    Increase meaningfully
    medium materiality
    High
    Capitalized Costs
    Trend down
    low materiality
    High

    Operational metrics

    14
    Cash, cash equivalents and investments
    $2.4B
    Q4 FY25

    Reported balance as of year-end.

    Net proceeds from public equity offering
    $600.2M
    February 2026

    Strengthened balance sheet subsequent to year-end.

    Long-term investment in U.S. manufacturing and services
    Up to $1B
    Long-term

    Part of a long-term investment strategy.

    VAX-31 Adult PCV OPUS trials total enrollment
    ~6,000
    Ongoing

    Across OPUS-1, OPUS-2, and OPUS-3 studies.

    VAX-31 Infant Phase II study enrollment
    900
    Completed

    Infants dosed in the optimized dose arm.

    Group A Strep annual deaths worldwide
    >600,000
    Annual

    Underscores the importance of advancing a preventative vaccine approach.

    Group A Strep annual cases worldwide
    800M
    Annual

    Underscores the importance of advancing a preventative vaccine approach.

    Group A Strep annual U.S. healthcare and productivity costs
    >$6B
    Annual

    Substantial medical and economic impact in the United States.

    VAX-31 Infant PCV coverage of IPD and AOM
    >90%significant increase over today's standard of care
    Future

    Designed to cover a significant percentage of disease due to strep pneumoniae.

    VAX-31 Adult PCV serotypes
    31
    Current

    Designed to provide broad coverage.

    VAX-31 incremental serotypes over PCV20/21
    10 or 11over study comparators
    Current

    Bringing additional serotypes to the equation for broader coverage.

    VAX-24 Phase II common serotypes directionally higher
    18directionally higher vs Prevnar 20
    Phase II

    Showed consistently higher immune responses.

    VAX-24 Phase II common serotypes statistically significantly higher
    7statistically significantly higher vs Prevnar 20
    Phase II

    Showed consistently higher immune responses.

    VAX-31 Adult PCV coverage of circulating disease
    95% to 98%
    Future

    When launched, VAX-31 is expected to cover a high percentage of circulating pneumococcal disease.

    Risks & headwinds

    3
    Total expenses, particularly R&D, to increase meaningfully in 2026.FY26

    Meaningfully relative to both full year 2025 and fourth quarter 2025 annualized levels.

    Mitigation: Driven by increased manufacturing spend for commercial readiness (including VAX-31 commercial supply build-up) and higher clinical spend for multiple VAX-31 adult Phase III studies and the Phase II infant study.

    Capitalized costs expected to trend down in 2026, with majority of costs related to dedicated manufacturing facility becoming expensed.FY26

    Trend down in 2026 compared to 2025.

    Mitigation: Completion of dedicated large-scale manufacturing facility build-out with Lonza.

    Serotype 3 continues to be the top circulating serotype despite inclusion in vaccines, due to insufficient antibody responses from any vaccine.Ongoing

    Outlier in the entire pneumococcal space.

    Mitigation: VAX-31's serotype 3 responses looked better than Prevnar 20 in prior studies; company does not expect it to be a competitive differentiator as no vaccine has meaningfully solved it.

    What to watch in Q1 FY26

    5

    VAX-31 Adult PCV (OPUS-1) Top-line Data

    Q4 2026
    CurrentOngoing Phase III study
    TargetAnnouncement of top-line safety, tolerability, and immunogenicity data

    Why it matters

    This pivotal study's results will be foundational for the BLA submission and will establish VAX-31's profile against current standards of care.

    In December, we initiated OPUS-1, our pivotal noninferiority study and expect to announce top line safety, tolerability and immunogenicity data in the fourth quarter of this year.

    Q&A highlights

    7

    How is OPUS-1 powered for noninferiority against PCV20 and PCV21 independently, and what remains to be discussed with FDA for the manufacturing consistency study?

    OPUS-1 is powered with high confidence against PCV20 based on prior data, and against PCV21 by looking at their comparisons to PCV20. For the 10 common serotypes, noninferiority to either comparator is sufficient. For incremental serotypes, VAX-31 has a strong profile. Management emphasized that perfection is not required for approval, as totality of data and broader coverage are key. Manufacturing consistency discussions with FDA are constructive and tracking well for BLA timing.

    “A successful result, as we pointed out in the call today, is not perfection, right? No pneumococcal conjugate vaccine has ever had a perfect slate of comparisons to the standard of care vaccines. These vaccines are approved based on the totality of what they offer over and above the standard of care vaccines.”

    asked by Jiale Song · answered by Grant Pickering

    2 min read6 chapters

    Detailed Narrative

    01

    PCV Franchise Strategy

    Vaxcyte is focused on developing broader spectrum pneumococcal conjugate vaccines (PCVs) to address persistent gaps in serotype coverage, particularly for adults and infants. The company aims to set a new standard by protecting against both historically and currently circulating serotypes while maintaining robust immune responses, leveraging its carrier-sparing platform.

    02

    Adult PCV Program (VAX-31 OPUS Phase III)

    The OPUS program (OPUS-1, OPUS-2, OPUS-3) is designed to support a BLA submission for VAX-31 in adults. OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Prevnar 20 and Capvaxive, aiming for a best-in-class profile. OPUS-2 evaluates concomitant administration with seasonal influenza vaccine, and OPUS-3 assesses VAX-31 in adults previously vaccinated with lower valency PCVs, potentially enabling a catch-up📎 recommendation.

    03

    Infant PCV Program (VAX-31 Phase II)

    Following learnings from the VAX-24 Phase II study, the VAX-31 infant Phase II study was modified to include an optimized dose arm with higher doses to enhance immune responses. Enrollment is complete with 900 infants dosed, and data is expected by mid-2027. VAX-31 is designed to cover over 90% of invasive pneumococcal disease and acute otitis media in U.S. children.

    04

    Manufacturing & Commercial Readiness

    Vaxcyte has completed the construction of a dedicated large-scale manufacturing facility on time and budget, designed to support global commercial demand. A high-volume fill-finish production line is also being built in North Carolina as part of a long-term $1 billion investment. The company is scaling its organization, including appointing a Chief Commercial Officer, to prepare for a successful commercial launch.

    05

    VAX-A1 Group A Strep Program Resumption

    Vaxcyte plans to resume development of its VAX-A1 Group A Strep vaccine candidate, which was previously paused for financial reasons. A Phase I study in adults is expected to initiate this year in Australia, focusing on safety and tolerability, given the significant global morbidity and mortality caused by Group A Strep.

    06

    Financial Strength & Policy Engagement

    The company reported a strong cash position of $2.4 billion as of Q4 FY25, further bolstered by a $600.2 million public equity offering, extending its cash runway to at least the end of 2028. Vaxcyte is also actively engaging with policymakers and public health stakeholders to advocate for science-based vaccine policy and domestic manufacturing readiness.

    AI-generated summary of the company’s earnings call. Not investment advice.